Medicament contra l'obesitat (Catalan Wikipedia)

Analysis of information sources in references of the Wikipedia article "Medicament contra l'obesitat" in Catalan language version.

refsWebsite

Global rank Catalan rank

4^th place

7^th place

2^nd place

6^th place

5^th place

3,258^th place

5,113^th place

doi.org

Ryan, Donna H. «Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?». Journal of Obesity & Metabolic Syndrome, vol. 30, 3, 9-2021, pàg. 196–208. DOI: 10.7570/jomes21033. ISSN: 2508-6235. PMC: 8526285. PMID: 34518444.
Jimenez-Munoz, Carlos M.; López, Marta; Albericio, Fernando; Makowski, Kamil «Targeting Energy Expenditure—Drugs for Obesity Treatment». Pharmaceuticals, vol. 14, 5, 5-2021, pàg. 435. DOI: 10.3390/ph14050435. ISSN: 1424-8247. PMC: 8148206. PMID: 34066399.
Müller, Timo D.; Blüher, Matthias; Tschöp, Matthias H.; DiMarchi, Richard D. «Anti-obesity drug discovery: advances and challenges». Nature Reviews Drug Discovery, vol. 21, 3, 3-2022, pàg. 201–223. DOI: 10.1038/s41573-021-00337-8. PMC: 8609996. PMID: 34815532.

Ryan, Donna H. «Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?». Journal of Obesity & Metabolic Syndrome, vol. 30, 3, 9-2021, pàg. 196–208. DOI: 10.7570/jomes21033. ISSN: 2508-6235. PMC: 8526285. PMID: 34518444.
Jimenez-Munoz, Carlos M.; López, Marta; Albericio, Fernando; Makowski, Kamil «Targeting Energy Expenditure—Drugs for Obesity Treatment». Pharmaceuticals, vol. 14, 5, 5-2021, pàg. 435. DOI: 10.3390/ph14050435. ISSN: 1424-8247. PMC: 8148206. PMID: 34066399.
Müller, Timo D.; Blüher, Matthias; Tschöp, Matthias H.; DiMarchi, Richard D. «Anti-obesity drug discovery: advances and challenges». Nature Reviews Drug Discovery, vol. 21, 3, 3-2022, pàg. 201–223. DOI: 10.1038/s41573-021-00337-8. PMC: 8609996. PMID: 34815532.

Ryan, Donna H. «Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?». Journal of Obesity & Metabolic Syndrome, vol. 30, 3, 9-2021, pàg. 196–208. DOI: 10.7570/jomes21033. ISSN: 2508-6235. PMC: 8526285. PMID: 34518444.
Jimenez-Munoz, Carlos M.; López, Marta; Albericio, Fernando; Makowski, Kamil «Targeting Energy Expenditure—Drugs for Obesity Treatment». Pharmaceuticals, vol. 14, 5, 5-2021, pàg. 435. DOI: 10.3390/ph14050435. ISSN: 1424-8247. PMC: 8148206. PMID: 34066399.